spacer
home > ebr > spring 2002 > has biotechnology forgotten the eye?
PUBLICATIONS
European Biopharmaceutical Review

Has Biotechnology Forgotten the Eye?

For over two decades, the biotechnology industry has been developing therapeutic products based on large molecules. The majority of these products are proteins, from the first trailblazers such as insulin and growth hormone, to the blockbusters like EPO, and subsequently wider classes of molecules such as cytokines, enzymes and antibodies. Yet in all this time, there have been few chronic clinical studies of proteins in eye disease. This is not because the markets are unattractive. Millions of patients suffer from poorly treated diseases in ophthalmology - such as age-related macular degeneration (AMD), or diabetic retinopathy - yet there are still very few medical treatments available. The exception that clearly demonstrates the attractive nature of the ophthalmology market is Visudyne’, developed by QLT Therapeutics Inc. and Novartis. The product transformed QLT from a small Canadian cancer company into a significantly capitalised, internationally known biotech company. This change occurred when the QLT concept of photodynamic therapy, which had previously been applied for several years to cancer with limited success, was applied to AMD. So given this success, why is biotech activity so limited in the eye?


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Tom S Shepherd, President and Chief Executive Officer of Neurotech S.A.

Dr Tom Shepherd is President and Chief Executive Officer of Neurotech S.A., a French-based biotechnology company based in the Genopole science park in Evry near Paris, with a US R&D subsidiary based in Lincoln, Rhode Island. Prior to joining the company in 1998, he was Vice President of Business Development at Intrabiotics Inc, a Californian biotech company now quoted on Nasdaq.
Tom gained his PhD in Biochemistry from the University of Strathclyde in Glasgow, UK, and has 20 years of international management experience in pharmaceuticals and biotechnology, having worked in the UK, the US, Australia, South Korea and France, with a range of companies including Sandoz (now Novartis), Cortecs plc, and ICN Pharmaceuticals.

spacer
Dr Tom S Shepherd
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Entry now open for the PPMA Group Industry Awards 2019

The 2019 PPMA Group Industry Awards will be held at the National Conference Centre (NEC), Birmingham, on the evening of the first day of the PPMA Total Show 2019 – Tuesday, 1 October 2019. 
More info >>

White Papers

What Your Clinical Study Design Reveals About Your Clinical Packaging Needs

PCI Pharma Services

As the cost and complexities of drug development increase, so do the challenges of global clinical trials. Today’s sponsors must be able to manage and coordinate multiple resources, processes, and locations with speed and accuracy to design effective and efficient clinical trials. Securing a stable supply chain to deal with the uncertainties of clinical trials is critical. One misstep can have a profound impact not only on the cost and time of your trial but also on its overall success.
More info >>

 
Industry Events

Nordic Life Science Days 10/12 September 2019

10-12 September 2019, Malmo Sweden

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement